Table 1 The characteristics of study participants
Characteristic | Total (N = 237) | NLR | P value | ||
|---|---|---|---|---|---|
Low (n = 79) | Middle (n = 79) | High (n = 79) | |||
Median age, y (IQR) | 70.0 (63.0–76.0) | 70.0 (63.5–76.0) | 70.0 (58.5–76.0) | 72.0 (64.0–77.0) | 0.646 |
Men, n (%) | 147 (62.0) | 48 (60.8) | 52 (65.8) | 47 (59.5) | 0.686 |
Medical history, n (%) | |||||
 Hypertension | 157 (66.2) | 52 (65.8) | 57 (72.1) | 48 (60.8) | 0.316 |
 Diabetes | 34 (14.4) | 11 (13.9) | 10 (12.7) | 13 (16.5) | 0.786 |
 Atrial fibrillation | 117 (49.4) | 41 (51.9) | 43 (54.4) | 33 (41.8) | 0.242 |
 Coronary heart disease | 27 (11.4) | 8 (10.1) | 12 (15.2) | 7 (8.9) | 0.416 |
 Stroke | 40 (16.9) | 18 (22.8) | 8 (10.1) | 14 (17.7) | 0.102 |
 Chronic kidney disease | 5 (2.1) | 1 (1.3) | 2 (2.5) | 2 (2.5) | 1.000 |
 Carotid artery disease | 8 (3.4) | 2 (2.5) | 2 (2.5) | 4 (5.1) | 0.736 |
 Current antiplatelet therapy | 22 (9.3) | 10 (12.7) | 4 (5.1) | 8 (10.1) | 0.246 |
 Current anticoagulation therapy | 16 (6.8) | 6 (7.6) | 7 (8.9) | 3 (3.8) | 0.418 |
Clinical characteristics | |||||
 Median baseline NIHSS score (IQR) | 15.0 (10.0–20.0) | 12.0 (10.0–17.0) | 14.0 (10.0–20.0) | 16.0 (12.0–20.0) | 0.028 |
 Median ASPECTS (IQR) | 8.0 (7.0–9.0) | 8.0 (8.0–9.0) | 8.0 (7.0–9.0) | 8.0 (7.0–9.0) | 0.027 |
 Mean systolic blood pressure at admission ± SD, mmHg | 151.1 ± 24.4 | 150.8 ± 27.4 | 152.9 ± 24.0 | 149.7 ± 21.9 | 0.519 |
 Mean diastolic blood pressure at admission ± SD, mmHg | 87.8 ± 14.5 | 87.0 ± 17.1 | 89.1 ± 12.1 | 87.3 ± 13.9 | 0.494 |
Mean glucose at admission ± SD, mmol/l | 7.8 ± 2.9 | 7.3 ± 1.9 | 7.6 ± 2.5 | 8.3 ± 3.8 | 0.195 |
Cause of stroke, n (%) | Â | Â | Â | Â | 0.818 |
 Cardioembolic | 141 (59.5) | 44 (55.7) | 48 (60.8) | 49 (62.0) |  |
 Intracranial atherosclerosis | 54 (22.8) | 20 (25.3) | 18 (22.8) | 16 (20.3) |  |
 Other | 42 (17.7) | 15 (19.0) | 13 (16.5) | 14 (17.7) |  |
Location of occlusion, n (%) | Â | Â | Â | Â | 0.760 |
 Internal carotid artery | 92 (38.8) | 30 (38.0) | 34 (43.0) | 28 (35.4) |  |
 Middle cerebral artery M1 segment | 103 (43.5) | 32 (40.5) | 34 (43.0) | 37 (46.9) |  |
 Middle cerebral artery M2 segment | 35 (14.8) | 13 (16.5) | 10 (12.7) | 12 (15.2) |  |
 Anterior cerebral artery A1 segment | 7 (3.0) | 4 (5.1) | 1 (1.3) | 2 (2.5) |  |
Bridging intravenous thrombolysis, n (%) | 24 (10.1) | 9 (11.4) | 4 (5.1) | 11 (14.0) | Â |
Collateral circulation, n (%) | Â | Â | Â | Â | 0.111 |
 ASITN/SIR 0–2 | 189 (79.8) | 57 (72.2) | 65 (82.3) | 67 (84.8) |  |
 ASITN/SIR 3–4 | 48 (20.3) | 22 (27.9) | 14 (17.7) | 12 (15.2) |  |
Complications during hospitalization, n (%) | |||||
 Pneumonia | 98 (41.4) | 29 (36.7) | 36 (45.6) | 33 (41.8) | 0.525 |
 Urinary tract infection | 5 (2.1) | 1 (1.3) | 2 (2.5) | 2 (2.5) | 1.000 |
 Sepsis | 6 (2.5) | 1 (1.3) | 3 (3.8) | 2 (2.5) | 0.873 |
 Any intracerebral hemorrhage | 102 (43.0) | 27 (34.2) | 29 (36.7) | 46 (58.2) | 0.004 |
 Symptomatic intracerebral hemorrhage | 19 (8.0) | 5 (6.3) | 5 (6.3) | 9 (11.4) | 0.400 |
Treatment during hospitalization,n (%) | |||||
 Anticoagulation | 64 (27.0) | 24 (30.4) | 20 (25.3) | 20 (25.3) | 0.710 |
 Dialysis | 1 (0.4) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 1.000 |
 Invasive mechanical ventilation | 51 (21.5) | 12 (15.2) | 16 (20.3) | 23 (29.1) | 0.098 |
 Vasopressors | 40 (16.9) | 9 (11.4) | 11 (13.9) | 20 (25.3) | 0.045 |
Mortality at 1 moth, n(%) | 42 (17.7) | 10 (12.7) | 12 (15.2) | 20 (25.3) | 0.088 |